Phase 2 trial data published in 2023 in the New England Journal of Medicine (Jastreboff et al., NEJM 2023) reported mean weight reductions of up to approximately 24% over 48 weeks in adults with obesity notably higher than results seen with currently approved agents
Topical vs Injectable Tolerability Topical GHK-Cu appears better tolerated than injectable forms, with topical side effects typically limited to mild redness, itching, or irritation at application site and rare copper uglies phenomenon (anecdotal accelerated skin aging appearance due to potential MMP upregulation, not well-studied)
Why NAD+ draws research interest These are the directions researchers and the peptide community most often explore NAD+ for so you know youre in the right place
A lipotropic skinny shot is a better fit if you are looking for metabolic support in addition to an energy boost
Antiarrhythmic Sotalol, Occlusion/Occlusion-like Syndrome in Rats, and Stable Gastric Pentadecapeptide BPC 157 Therapy
